Home › Companies › Corvus Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Corvus Pharmaceuticals, Inc.’s Form 8-K, filed 2026-06-12 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Proxy season: 2025-2026
Explore Corvus Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Corvus Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-12 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Richard A. Miller, M.D. | 58,275,179 | -- | -- | 2,697,052 | 12,049,623 | Majority: yes |
| Elect Director: Linda S. Grais, M.D., J.D. | 53,185,380 | -- | -- | 7,786,851 | 12,049,623 | Majority: yes |
| Proposal 2: Ratification of Selection of Independent Registered Accounting Firm The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending Decem | 72,864,335 | 105,674 | 51,845 | -- | -- | Majority: yes |
| Proposal 3: Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers On a non-binding advisory basis, the Company's stockholders approved the compensation of the Company's named executive officers. | 58,936,532 | 1,971,370 | 64,329 | -- | 12,049,623 | Majority: yes |
Source: Corvus Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-06-12 — read the filing on EDGAR.
Each item below shows how the 174 asset managers that disclosed a Corvus Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Corvus Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Non-Binding Advisory Vote to Approve the Compensation of the Company's Named Executive Officers On a non-binding advisory basis, the Company's stockholders approved the compensation of the Company's named exe”): 58,936,532 for, 1,971,370 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 84,090,424 outstanding shares: 70% for, 2% against (72% of the company cast a for/against vote).
The 174 asset managers below cast 99.4% of the shares they voted on this item FOR (49,587,396 for, 278,957 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 7,165,006 | 0 | 0 | 0 | For |
| Vanguard | 4,428,463 | 6 | 0 | 0 | For |
| T. Rowe Price | 4,309,522 | 0 | 0 | 0 | For |
| BlackRock | 3,471,387 | 12,742 | 0 | 0 | For |
| Vivo Capital, LLC | 2,805,816 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 2,487,775 | 0 | 0 | 0 | For |
| Commodore Capital LP | 2,258,735 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 2,094,764 | 0 | 0 | 0 | For |
| Foresite Capital Management VI LLC | 1,831,233 | 0 | 0 | 0 | For |
| Wellington | 1,617,761 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 1,589,593 | 0 | 0 | 0 | For |
| State Street | 1,352,433 | 2,559 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,269,389 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 1,263,045 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 1,255,921 | 0 | 0 | 0 | For |
| Fidelity | 1,024,763 | 0 | 0 | 0 | For |
| Catalio Capital Management, LP | 869,748 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 806,415 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 575,092 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 550,000 | 0 | 0 | 0 | For |
| Blue Owl Capital Holdings LP | 510,000 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 428,885 | 0 | 0 | 0 | For |
| Charles Schwab | 376,223 | 0 | 0 | 0 | For |
| Hartford | 299,985 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 288,612 | 0 | 0 | 0 | For |
Showing the 25 largest of 174 asset managers. See all 174 in the interactive database.
Combines 5 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Corvus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Linda S. Grais, M.D., J.D.”): 53,185,380 for, 7,786,851 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 84,090,424 outstanding shares: 63% for, 9% withheld (73% of the company cast a for/withheld vote).
The 59 asset managers below cast 100% of the shares they voted on this item FOR (9,619,543 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,874,948 | 0 | 22 | 0 | For |
| T. Rowe Price | 1,700,288 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 1,161,450 | 0 | Abstain |
| Fidelity | 1,021,353 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 806,415 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 550,000 | 0 | 0 | 0 | For |
| State Street | 1,336 | 0 | 410,292 | 0 | Abstain |
| Hartford | 299,985 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 0 | 288,612 | 0 | Abstain |
| Charles Schwab | 188,094 | 0 | 0 | 0 | For |
| Principal | 4,299 | 0 | 170,641 | 0 | Abstain |
| Equitable | 12,357 | 0 | 144,538 | 0 | Abstain |
| TIAA | 0 | 0 | 142,018 | 0 | Abstain |
| Victory Capital | 129,967 | 0 | 0 | 0 | For |
| Goldman Sachs | 111,984 | 0 | 0 | 0 | For |
| Tema ETF Trust | 109,881 | 0 | 0 | 0 | For |
| Brighthouse | 89,445 | 0 | 5,395 | 0 | For |
| John Hancock | 93,527 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 79,056 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 77,046 | 0 | Abstain |
| Voya | 73,427 | 0 | 0 | 0 | For |
| ProShares | 62,063 | 0 | 0 | 0 | For |
| Lincoln Financial | 9,404 | 0 | 39,400 | 0 | Abstain |
| JPMorgan | 42,768 | 0 | 0 | 0 | For |
| Transamerica | 40,700 | 0 | 0 | 0 | For |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
Combines 4 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Corvus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Richard A. Miller, M.D.”): 58,275,179 for, 2,697,052 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 84,090,424 outstanding shares: 69% for, 3% withheld (73% of the company cast a for/withheld vote).
The 59 asset managers below cast 100% of the shares they voted on this item FOR (11,646,448 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,865,150 | 0 | 9,821 | 0 | For |
| T. Rowe Price | 1,700,288 | 0 | 0 | 0 | For |
| BlackRock | 1,161,450 | 0 | 0 | 0 | For |
| Fidelity | 1,021,353 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 806,415 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 550,000 | 0 | 0 | 0 | For |
| State Street | 411,082 | 0 | 546 | 0 | For |
| Hartford | 299,985 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 0 | 288,612 | 0 | Abstain |
| Charles Schwab | 188,094 | 0 | 0 | 0 | For |
| Principal | 4,299 | 0 | 170,641 | 0 | Abstain |
| Equitable | 156,895 | 0 | 0 | 0 | For |
| TIAA | 142,018 | 0 | 0 | 0 | For |
| Victory Capital | 129,967 | 0 | 0 | 0 | For |
| Goldman Sachs | 111,984 | 0 | 0 | 0 | For |
| Tema ETF Trust | 109,881 | 0 | 0 | 0 | For |
| Brighthouse | 89,445 | 0 | 5,395 | 0 | For |
| John Hancock | 93,527 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 79,056 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 77,046 | 0 | 0 | 0 | For |
| Voya | 73,427 | 0 | 0 | 0 | For |
| ProShares | 62,063 | 0 | 0 | 0 | For |
| Lincoln Financial | 48,804 | 0 | 0 | 0 | For |
| JPMorgan | 42,768 | 0 | 0 | 0 | For |
| Transamerica | 40,700 | 0 | 0 | 0 | For |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Corvus Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: Ratification of Selection of Independent Registered Accounting Firm The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the ”): 72,864,335 for, 105,674 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 84,090,424 outstanding shares: 87% for, 0.2% against (87% of the company cast a for/against vote).
The 59 asset managers below cast 99.9% of the shares they voted on this item FOR (12,155,572 for, 16 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,874,970 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,700,288 | 0 | 0 | 0 | For |
| BlackRock | 1,161,450 | 0 | 0 | 0 | For |
| Fidelity | 1,021,353 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 806,415 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 550,000 | 0 | 0 | 0 | For |
| State Street | 411,612 | 16 | 0 | 0 | For |
| Hartford | 299,985 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 288,612 | 0 | 0 | 0 | For |
| Charles Schwab | 188,094 | 0 | 0 | 0 | For |
| Principal | 174,940 | 0 | 0 | 0 | For |
| Equitable | 156,895 | 0 | 0 | 0 | For |
| TIAA | 142,018 | 0 | 0 | 0 | For |
| Victory Capital | 129,967 | 0 | 0 | 0 | For |
| Goldman Sachs | 111,984 | 0 | 0 | 0 | For |
| Tema ETF Trust | 109,881 | 0 | 0 | 0 | For |
| Brighthouse | 89,445 | 0 | 5,395 | 0 | For |
| John Hancock | 93,527 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 79,056 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 77,046 | 0 | 0 | 0 | For |
| Voya | 73,427 | 0 | 0 | 0 | For |
| ProShares | 62,063 | 0 | 0 | 0 | For |
| Lincoln Financial | 48,804 | 0 | 0 | 0 | For |
| JPMorgan | 42,768 | 0 | 0 | 0 | For |
| Transamerica | 40,700 | 0 | 0 | 0 | For |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
Ranked by the number of Corvus Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 84,090,424 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 8.52% |
| 2 | Vanguard | 5.27% |
| 3 | T. Rowe Price | 5.12% |
| 4 | BlackRock | 4.14% |
| 5 | Vivo Capital, LLC | 3.34% |
| 6 | Deep Track Capital, LP | 2.96% |
| 7 | Commodore Capital LP | 2.69% |
| 8 | Polar Capital Holdings Plc | 2.49% |
| 9 | Foresite Capital Management VI LLC | 2.18% |
| 10 | Wellington | 1.92% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| OrbiMed Private Investments V, LP | 8.52% | DEF14A |
| Peter A. Thompson, M.D. | 8.52% | DEF14A |
| Entities affiliated with Sirenia Capital Management LP | 8.12% | DEF14A |
| BlackRock | 7.33% | 13F |
| Richard A. Miller | 7.24% | 13G |
| Vanguard Group | 4.61% | 13F |
| Morgan Stanley | 4.24% | 13F |
| State Street | 4.24% | 13F |
| Adams Street Partners, LLC | 3.90% | 13D |
| T. Rowe Price | 3.47% | 13F |
Percentages above are of 84,090,424 shares outstanding, as reported by Corvus Pharmaceuticals, Inc. on its Form 10-Q dated 2026-05-07 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Corvus Pharmaceuticals, Inc.’s 10-Q dated 2026-05-07. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At Corvus Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-11, in the 2025-2026 proxy season, 174 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 891 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers. — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Corvus Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-12.
Corvus Pharmaceuticals, Inc. proxy season coverage: 2025-2026 (this page).